Avisa Diagnostics Inc.

As of June 30, 2021, Avisa Diagnostics Inc. has 2.75M shares outstanding.

As of June 30, 2021, Avisa Diagnostics Inc. trades at a trailing price-to-earnings ratio of 2.26.

As of June 30, 2021, Avisa Diagnostics Inc. maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -112.92, indicating conservative leverage, while an interest coverage ratio of -10.90 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2021. Return on assets (ROA) is negative at -227.24, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -10.39, pointing to unprofitable operations over the period.

These figures cover the twelve months ended June 30, 2021. Free cash flow yield is negative at -25.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 16.53, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Avisa Diagnostics Inc. shareholders.

Avisa Diagnostics Inc.'s most recent stock split took place on May 18, 2021 with a 15:1 split ratio.

As of June 30, 2021, Avisa Diagnostics Inc. has an Altman Z-Score of -21.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.